According to the wise folks at Santiment’s ETF dashboard, a whopping $11.9 million decided to take a hike in a single session. That’s right, the second-largest daily outflow since these products started keeping tabs. Imagine the embarrassment! It’s like being stood up at the prom, but with more zeros.
CoreWeave began, rather humbly, as a miner of Ethereum (ETH +0.36%). A pursuit, one might say, akin to chasing moonbeams. The cryptocurrency crash of 2018, however, proved a bracing corrective. They wisely abandoned the ephemeral realm of digital coinage and repurposed their graphical processing units – those glittering engines of calculation – to the far more profitable task of tending the burgeoning AI gardens. A shrewd pivot, indeed. In 2022, they invested a cool $100 million in Nvidia’s (NVDA +3.41%) H100 GPUs – a rather extravagant purchase, but one, it appears, justified by results. They then, with a touch of financial legerdemain, leveraged these acquisitions as collateral, securing further funding to expand their empire of silicon and electricity.
Micron Technology (MU 0.87%) occupies a critical position within this landscape as a supplier of memory solutions essential to AI hardware. Prior commentary has addressed the company’s historical trajectory. This analysis focuses on recent financial performance and the potential for continued growth, acknowledging the inherent cyclicality of the sector.
Alphabet, a behemoth casting a long shadow, has declared its intent – a disbursement of $175 to $185 billion this year. It is a spring thaw of investment, following a long winter of cautious restraint, a signal that the fever of artificial intelligence has taken root and now blossoms, demanding sustenance.
Archer Aviation, they called it. A name that suggested a swiftness, a grace, that seemed to mock the laborious process of bringing a novel aircraft into being. They spoke of Midnight, a vessel intended to liberate the city dweller from the tyranny of traffic, to carry them aloft on currents of electricity. A beautiful vision, certainly, but one that had already begun to fray at the edges, like a handwoven tapestry exposed to the relentless sun. Seven years they had labored, building not just a machine, but a legend, a story told in balance sheets and regulatory filings. And yet, the stock, that fickle barometer of hope, had offered a meager return to those who had dared to believe, a 35% decline from the initial offering price of $10. The S&P 500, that stoic giant, had doubled its value in the same span, a silent rebuke to the more audacious venture.
The market, naturally, has been twitchy. Down over 10% this year. Below $500. A dip. A flicker. Is it a steal? A trap? Let’s be honest, “bargain” and “biotech” rarely occupy the same sentence. It’s like trusting a politician with your life savings. Possible, but profoundly unwise. I’ve seen too many “sure things” dissolve into vaporware. But this…this is different. This is surgery. People will always need their innards tinkered with. That’s a fundamental truth. A grim, lucrative truth.
SLVP, you see, doesn’t actually hold the silver. It holds shares in the companies that do the digging. Which introduces a delightful layer of inefficiency. They have to pay people, maintain equipment, and occasionally deal with geological surprises. IAU, on the other hand, is simpler. It’s essentially a very large, heavily guarded vault.2 This comparison is less about finding the ‘best’ investment and more about understanding the different flavours of hope and despair on offer.
Behold, the proletariat of blockchain has spoken, and Solana is their champion. According to the wise sages at DefiLlama, this network has ascended to the throne, generating $30.93 million in weekly app revenue and a staggering $36.015 billion in DEX trades. The old guard trembles as the new king struts his stuff.
Now, this here stock had been climbin’ like a monkey up a greased pole – a good 50% rise in the last six months! – so this fallin’ ain’t entirely unexpected. It did rally a bit, mind you, but as of this mornin’, it was still down nearly 20%. A good reminder, if you ask me, that fortunes can change faster than a politician’s promise.
The fund’s holdings now represent 88.4% of their reported portfolio. A substantial weighting, certainly, though one must remember that these firms operate on a scale beyond our comprehension. A holding of $525.96 million, while considerable to us, is but a single brushstroke on a canvas already richly adorned with other ventures – Agilon Health, for instance, accounting for a further $69.00 million. It is a reminder that even the most concentrated positions are relative, and that the true scope of their strategy remains veiled.